Armata Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
ARMP$3.75-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
Three and Six Months Ended June 30, 2025 and 2024
(in thousands, except share data)
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Stockholders’ Deficit | ||||||||||||||
| · · Common Stock · · · · · · · · · | ||||||||||||||
| · · · · · · · Additional · · · · Total | ||||||||||||||
| · · · · · · · Paid-in · · Accumulated · · Stockholders’ | ||||||||||||||
| · Shares · Amount · Capital · Deficit · Deficit | ||||||||||||||
| Balances, March 31, 2024 | 36,132,117 | | $361 | | $276,969 | | $(333,840) | | $(56,510) | |||||
| Exercise of stock options | | 23,875 | | | 1 | | | 87 | | | — | | | 88 |
| Stock-based compensation expense | — | | | — | | | 1,335 | | | — | | | 1,335 | |
| Net income | — | | | — | | | — | | | 8,986 | | | 8,986 | |
| Balances, June 30, 2024 | 36,155,992 | | $362 | | $278,391 | | $(324,854) | | $(46,101) | |||||
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | Stockholders’ Deficit | ||||||||||||
| | | Common Stock | | | | | | | | | | |||
| | | | | | | | Additional | | | | Total | |||
| | | | | | | | Paid-in | | Accumulated | | Stockholders’ | |||
| | Shares | Amount | Capital | Deficit | Deficit | |||||||||
| Balances, March 31, 2025 | 36,193,479 | | $362 | | $280,121 | | $(334,266) | | $(53,783) | |||||
| Stock-based compensation expense | — | | | — | | | 575 | | | — | | | 575 | |
| Net loss | — | | | — | | | — | | | (16,295) | | | (16,295) | |
| Balances, June 30, 2025 | 36,193,479 | | $362 | | $280,696 | | $(350,561) | | $(69,503) | |||||
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Stockholders’ Deficit | ||||||||||||||
| · · Common Stock · · · · · · · · · | ||||||||||||||
| · · · · · · · Additional · · · · Total | ||||||||||||||
| · · · · · · · Paid-in · · Accumulated · · Stockholders’ | ||||||||||||||
| · Shares · Amount · Capital · Deficit · Deficit | ||||||||||||||
| Balances, December 31, 2023 | 36,122,932 | | $361 | | $276,393 | | $(308,819) | | $(32,065) | |||||
| Exercise of stock options | | 37,282 | | | 1 | | | 129 | | | — | | | 130 |
| Withholdings for taxes related to net share settlement of equity awards | | (4,222) | | | — | | | — | | | — | | | — |
| Stock-based compensation expense | — | | | — | | | 1,869 | | | — | | 1,869 | ||
| Net loss | — | | | — | | | — | | | (16,035) | | (16,035) | ||
| Balances, June 30, 2024 | 36,155,992 | | $362 | | $278,391 | | $(324,854) | | $(46,101) | |||||
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | Stockholders’ Deficit | ||||||||||||
| | | Common Stock | | | | | | | | | | |||
| | | | | | | | Additional | | | | Total | |||
| | | | | | | | Paid-in | | Accumulated | | Stockholders’ | |||
| | | Shares | Amount | Capital | Deficit | Deficit | ||||||||
| Balances, December 31, 2024 | 36,183,067 | | $362 | | $279,354 | | $(327,735) | | $(48,019) | |||||
| Issuance of Common Stock upon release of restricted stock units, net of tax withholdings | | 10,412 | | | — | | | (14) | | | | | | (14) |
| Stock-based compensation expense | | — | | | — | | | 1,356 | | | — | | | 1,356 |
| Net loss | — | | | — | | | — | | | (22,826) | | | (22,826) | |
| Balances, June 30, 2025 | 36,193,479 | | $362 | | $280,696 | | $(350,561) | | $(69,503) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.